Clinical Trial Update: Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating sorafenib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma has terminated with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Mayo Clinic | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 1 | Status: TERMINATED | Results posted: 2011-12-26